Cargando…

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension

BACKGROUND: Liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) is influenced by liver fibrosis and hepatic perfusion pressure. VCTE-based controlled attenuation parameter (CAP) is a noninvasive marker for hepatic steatosis (HS). AIMS: To investigate the diagnostic pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Semmler, Georg, Stift, Judith, Scheiner, Bernhard, Wöran, Katharina, Schwabl, Philipp, Paternostro, Rafael, Bucsics, Theresa, Stättermayer, Albert Friedrich, Pinter, Matthias, Ferlitsch, Arnulf, Trauner, Michael, Reiberger, Thomas, Mandorfer, Mattias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858384/
https://www.ncbi.nlm.nih.gov/pubmed/31209721
http://dx.doi.org/10.1007/s10620-019-05702-7
_version_ 1783470948064690176
author Semmler, Georg
Stift, Judith
Scheiner, Bernhard
Wöran, Katharina
Schwabl, Philipp
Paternostro, Rafael
Bucsics, Theresa
Stättermayer, Albert Friedrich
Pinter, Matthias
Ferlitsch, Arnulf
Trauner, Michael
Reiberger, Thomas
Mandorfer, Mattias
author_facet Semmler, Georg
Stift, Judith
Scheiner, Bernhard
Wöran, Katharina
Schwabl, Philipp
Paternostro, Rafael
Bucsics, Theresa
Stättermayer, Albert Friedrich
Pinter, Matthias
Ferlitsch, Arnulf
Trauner, Michael
Reiberger, Thomas
Mandorfer, Mattias
author_sort Semmler, Georg
collection PubMed
description BACKGROUND: Liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) is influenced by liver fibrosis and hepatic perfusion pressure. VCTE-based controlled attenuation parameter (CAP) is a noninvasive marker for hepatic steatosis (HS). AIMS: To investigate the diagnostic performance of CAP in patients with advanced chronic liver disease (ACLD)/portal hypertension (PHT: hepatic venous pressure gradient (HVPG) ≥ 6 mmHg). METHODS: Eighty-eight patients with LS ≥ 10 kPa and/or HVPG ≥ 6 mmHg who underwent simultaneous liver biopsy, CAP, and HVPG measurement were included. HS was histologically graded according to the modified Brunt classification. RESULTS: Patient characteristics: Mean MELD:11 (standard derivation [SD] ± 4), median HVPG:16 (interquartile range [IQR]10–19) mmHg, median LS:27.4 (IQR 16.2–48.9) kPa, and mean CAP:221 (SD ± 75) dB/m. According to histology, 47 (53.4%) patients had no HS (S0), 28 (31.8%) had S1, 11 (12.5%) had S2, and 2 (2.3%) had S3. The area under the receiver operating characteristic curve (AUROC) of CAP for diagnosing any HS (S0 vs. ≥ S1) was 0.692 (95% confidence interval [95% CI] 0.582–0.802) in the overall cohort, 0.830 (95% CI 0.637–1.0) in patients with HVPG < 10 mmHg, and 0.629 (95% CI 0.497–0.761) in patients with clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg; n = 69). Using the established cutoff for any HS (248 dB/m), the sensitivity/specificity of CAP was only 48.8%/76.6%, respectively. In contrast, the AUROC and sensitivity/specificity (cutoff 268 dB/m) for diagnosing HS ≥ S2 were 0.842 (95% CI 0.747–0.936) and 84.6%/81.3%, respectively. CAP correlated with the percentage of steatotic hepatocytes (Spearman’s ρ = 0.402; p ≤ 0.001) and showed a weak correlation with liver stiffness (ρ = 0.225; p = 0.035). CONCLUSIONS: The diagnostic performance of CAP for any HS seems to be limited in patients with ACLD, if CSPH is present. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10620-019-05702-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6858384
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-68583842019-12-03 Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension Semmler, Georg Stift, Judith Scheiner, Bernhard Wöran, Katharina Schwabl, Philipp Paternostro, Rafael Bucsics, Theresa Stättermayer, Albert Friedrich Pinter, Matthias Ferlitsch, Arnulf Trauner, Michael Reiberger, Thomas Mandorfer, Mattias Dig Dis Sci Original Article BACKGROUND: Liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) is influenced by liver fibrosis and hepatic perfusion pressure. VCTE-based controlled attenuation parameter (CAP) is a noninvasive marker for hepatic steatosis (HS). AIMS: To investigate the diagnostic performance of CAP in patients with advanced chronic liver disease (ACLD)/portal hypertension (PHT: hepatic venous pressure gradient (HVPG) ≥ 6 mmHg). METHODS: Eighty-eight patients with LS ≥ 10 kPa and/or HVPG ≥ 6 mmHg who underwent simultaneous liver biopsy, CAP, and HVPG measurement were included. HS was histologically graded according to the modified Brunt classification. RESULTS: Patient characteristics: Mean MELD:11 (standard derivation [SD] ± 4), median HVPG:16 (interquartile range [IQR]10–19) mmHg, median LS:27.4 (IQR 16.2–48.9) kPa, and mean CAP:221 (SD ± 75) dB/m. According to histology, 47 (53.4%) patients had no HS (S0), 28 (31.8%) had S1, 11 (12.5%) had S2, and 2 (2.3%) had S3. The area under the receiver operating characteristic curve (AUROC) of CAP for diagnosing any HS (S0 vs. ≥ S1) was 0.692 (95% confidence interval [95% CI] 0.582–0.802) in the overall cohort, 0.830 (95% CI 0.637–1.0) in patients with HVPG < 10 mmHg, and 0.629 (95% CI 0.497–0.761) in patients with clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg; n = 69). Using the established cutoff for any HS (248 dB/m), the sensitivity/specificity of CAP was only 48.8%/76.6%, respectively. In contrast, the AUROC and sensitivity/specificity (cutoff 268 dB/m) for diagnosing HS ≥ S2 were 0.842 (95% CI 0.747–0.936) and 84.6%/81.3%, respectively. CAP correlated with the percentage of steatotic hepatocytes (Spearman’s ρ = 0.402; p ≤ 0.001) and showed a weak correlation with liver stiffness (ρ = 0.225; p = 0.035). CONCLUSIONS: The diagnostic performance of CAP for any HS seems to be limited in patients with ACLD, if CSPH is present. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10620-019-05702-7) contains supplementary material, which is available to authorized users. Springer US 2019-06-17 2019 /pmc/articles/PMC6858384/ /pubmed/31209721 http://dx.doi.org/10.1007/s10620-019-05702-7 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Semmler, Georg
Stift, Judith
Scheiner, Bernhard
Wöran, Katharina
Schwabl, Philipp
Paternostro, Rafael
Bucsics, Theresa
Stättermayer, Albert Friedrich
Pinter, Matthias
Ferlitsch, Arnulf
Trauner, Michael
Reiberger, Thomas
Mandorfer, Mattias
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
title Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
title_full Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
title_fullStr Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
title_full_unstemmed Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
title_short Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
title_sort performance of controlled attenuation parameter in patients with advanced chronic liver disease and portal hypertension
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858384/
https://www.ncbi.nlm.nih.gov/pubmed/31209721
http://dx.doi.org/10.1007/s10620-019-05702-7
work_keys_str_mv AT semmlergeorg performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT stiftjudith performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT scheinerbernhard performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT worankatharina performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT schwablphilipp performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT paternostrorafael performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT bucsicstheresa performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT stattermayeralbertfriedrich performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT pintermatthias performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT ferlitscharnulf performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT traunermichael performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT reibergerthomas performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension
AT mandorfermattias performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension